Key result
Acetylsalicylic acid increased fibrin network porosity and shortened fibrin clot lysis time in a low concentration-dependent manner, likely by altering fibrin monomer assembly to form thicker fibers.
Why the study?
Does acetylsalicylic acid improve fibrin network porosity and fibrinolysis in purified fibrinogen?
Does acetylsalicylic acid improve fibrin network porosity and fibrinolysis in purified fibrinogen?
Low concentrations of acetylsalicylic acid enhance fibrin network porosity and fibrinolysis by altering fibrin monomer assembly, an effect potentially antagonized by its hydrolytic product, salicylic acid.
Should not alter aspirin dosing; hypothesis-generating for fibrin effects in purified systems.
Our earlier study in vivo showed that a lower dose of acetylsalicylic acid (ASA) brought greater enhancement in fibrin gel permeability (Ks) than a higher dose. To assess whether this finding related to modifications of fibrinogen clotting property by ASA, purified fibrinogen was incubated with ASA and/or salicylic acid (SA). The fibrinogen product was examined. Fibrinogen "clotting time" was not affected. Shortening of fibrin clot "lysis time" paralleled the increase of fibrin network porosity demonstrated by measurements of liquid permeability (Ks), fibrin fiber thickness, and 3-dimensional microscopic image, in a low ASA concentration-dependent way. Ks levels were not altered by SA alone but significantly decreased in samples treated by both where the concentrations were low for ASA and high for SA. In conclusion, ASA at the concentrations used did not influence the rate of fibrinogen gelation by thrombin. However, assembly of fibrin monomers was most probably altered, leading to enhancement of fibrin fiber thickness. A looser network was constructed by the thicker fibrin fibers, which benefits fibrinolysis. According to the known mechanism that SA interferes with ASA in preventing acetylation of platelet's proteins, an explanation for the low ASA concentration-dependent effects on fibrin network structure may be that fewer molecules of SA-the hydrolytic product of ASA-are generated from lower doses of ASA, which block acetylation of fibrinogen to a smaller extent and thus more significantly impair fibrin formation.
No takes yet. Share an insight, caveat, or question.
He et al. (2009) studied this question. Acetylsalicylic acid (ASA) and/or salicylic acid (SA) was evaluated on Fibrin network porosity (Ks), fibrin fiber thickness, and fibrin clot lysis time. Acetylsalicylic acid increased fibrin network porosity and shortened fibrin clot lysis time in a low concentration-dependent manner, likely by altering fibrin monomer assembly to form thicker fibers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: